RMD Open

Risk of cognitive disorders in patients with primary Sjögren’s disease: data from Korean Health Insurance Service

Objective To investigate the risk of incident cognitive disorders in patients with primary Sjögren’s disease (pSjD) using nationwide Korean National Health Insurance Service data.Methods This ...
RMD Open

Early SLE may follow a fast comorbidity/multimorbidity trajectory associated with flare burden and glucocorticoid exposure

Background Patients with systemic lupus erythematosus (SLE) carry a substantial comorbidity load associated with worse prognosis, yet most evidence pertains to long-standing disease. How comorbidities ...
RMD Open

Distinct molecular signature in relapsed patients with ANCA-associated vasculitis

Objectives The pathogenesis of relapses in patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) remains ill defined. We aimed to identify whether there are any ...
rmdopen.bmj

Rheumatoid factor and anticitrullinated protein antibody status jointly influence the association between disease activity and cardiovascular risk in rheumatoid arthritis

Objectives Rheumatoid factor (RF) and anticitrullinated protein antibodies (ACPA) are linked to disease activity, severity and cardiovascular risk in rheumatoid arthritis (RA). Since RA-related ...
rmdopen.bmj

Gut microbiota dysbiosis and metabolic alterations in rheumatoid arthritis: a barrier to periodontal repair

Objective To investigate the impact of rheumatoid arthritis (RA) on periodontal healing and the underlying mechanisms. Methods Mandibular periodontal bone defect (PBD) and collagen-induced arthritis ...
rmdopen.bmj

A phase III, randomised, double-blind, multi-dose, placebo- and naproxen-controlled study to evaluate the efficacy and safety of fasinumab in patients with pain due to ...

Background Chronic pain due to osteoarthritis (OA) causes considerable burden, and current treatment options are limited. This phase III study aimed to compare the efficacy and safety of fasinumab, an ...
rmdopen.bmj

Spotlight on Sjögren’s: a patient perspective on burden of illness and unmet needs – results from a real-world survey

Objective Sjögren’s is a chronic systemic autoimmune disease characterised by dryness symptoms (eyes, mouth, skin), alongside other systemic manifestations such as fatigue, muscle and joint pain, ...
rmdopen.bmj

Persistent-relapsing SARS-CoV-2 infection following rituximab treatment for autoimmune rheumatic diseases: diagnosis and outcomes

Background COVID-19 may persist or relapse in patients on B-cell depleting biologic therapies. Objective To examine the rate and outcome of persistent-relapsing COVID-19 (prCOVID-19) in patients with ...
rmdopen.bmj

Patients with psoriatic arthritis and comorbid metabolic syndrome show a difficult-to-treat phenotype: another mosaic tile in the definition of a still undefined subset of patients

Objective Psoriatic arthritis (PsA) is a chronic inflammatory condition associated with psoriasis and characterised by heterogeneous clinical manifestations, including peripheral and axial arthritis, ...
rmdopen.bmj

Cluster analysis identifies three clinical patterns of patients with systemic autoimmune diseases and anti-Ku antibodies

Methods Anti-Ku-positive patients were retrieved through four immunology departments. Clusters were derived from unsupervised multiple correspondence analysis, not including the disease’s diagnosis, ...
rmdopen.bmj

Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment ...

Objectives To determine belimumab efficacy assessed using the British Isles Lupus Assessment Group (BILAG)-based Combined Lupus Assessment (BICLA) in patients with systemic lupus erythematosus (SLE) ...
rmdopen.bmj

Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies

Objective To assess the long-term safety profile of bimekizumab (BKZ) in patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). Methods Safety data pooled from six integrated ...